Edison Expands North American Healthcare Sector Coverage with ADR Report on MorphoSys

 Edison Expands North American Healthcare Sector Coverage with ADR Report on
                                  MorphoSys

  PR Newswire

  LONDON, August 16, 2013

LONDON, August 16, 2013 /PRNewswire/ --

Edison Investment Research, a leading international investment research firm,
announces the initiation of research coverage on the US-listed ADRs of
MorphoSys (NASDAQ: MPSYY), a German biotech company developing human
antibodies for therapeutic use.

 (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

The ADR initiation follows two landmark licensing deals struck with
GlaxoSmithKline and Celgene that mark a transformation of the company.
Edison's comprehensive report examines the investment merits of MorphoSys and
derives a valuation of $1,895m, equivalent to $39.70/ADR. MorphoSys has three
proprietary programs and 16 programs from antibody alliances in clinical
development. It also has a 10-year alliance with Novartis. For the full report
see: http://www.edisoninvestmentresearch.com/research/company/morphosys

The launch of ADR coverage on MorphoSys is part of a programme of ADR research
initiations on foreign-domiciled, US-listed biotech companies, which are
specifically tailored for US investors. Edison will continue to provide
research coverage in parallel on the Frankfurt-listed shares of MorphoSys.

Edison provides research coverage on more than 130 healthcare companies in
Europe, North America and Australia. Edison has pioneered a scientific,
detail-oriented approach to analysing companies in the healthcare sector that
is delivered in a concise and non-promotional manner. It aims to inform
investors, while providing a realistic assessment of the competitive strengths
and threats to key drug development programmes. All facts are carefully
sourced and the analysis is underpinned by comprehensive and rigorous
financial models. Edison's reports provide an overall company valuation
without any specific stock recommendation.

All reports published by Edison are available to download free of charge from
its website http://www.edisongroup.com .

About Edison Investment Research

Edison, the investment intelligence firm, is the future of investor
interaction with corporates. Our team of over 100 analysts and investment
professionals works with leading companies, fund managers and investment banks
worldwide to support its capital markets activity. We provide services to more
than 400 retained corporate and investor clients from our offices in London,
New York, Berlin, Sydney and Wellington. Edison is authorised and regulated by
the Financial Services Authority (
http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584 ).

Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any securities.

About MorphoSys

MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.

For more information please contact: Dr Mick Cooper Edison Investment Research
  +44(0)20-3077-5734 healthcare@edisongroup.com